142results about How to "Reduce pathological damage" patented technology

The invention relates to human sDR5-Fc recombinant fusion protein and application of the human sDR5-Fc recombinant fusion protein to preparation of medicine for preventing and treating drug induced liver injury. Through long-time study of the inventor, the protein gene sequence is selected again, and the novel human sDR5-Fc recombinant fusion protein provided by the invention is obtained. Through a great number of experiments, the human sDR5-Fc recombinant fusion protein can obviously reduce the serum transaminase level in various mouse drug induced liver injury models; the liver pathologic damage is reduced; the liver cell apoptosis rate is obviously reduced; the mouse survival ratio is improved. The human sDR5-Fc recombinant fusion protein is used as novel candidate medicine for preventing and treating the drug induced liver injury; the treatment range is wide; targets are specific; the action is special and fast; the curative effect is obvious; the safety is high; great development potential is realized.

The invention relates to a pharmaceutical composition containing folic acid and B vitamins and applications thereof in preparing medicines for preventing and treating hyperhomocysteinemia or diseases accompanied with homocysteine rise. The B vitamins are one or a plurality of vitamin B6, vitamin B12, vitamin B1, vitamin B2, vitamin PP, biotin and pantothenic acid. Folic acid and B vitamins can cooperate to reduce the Hcy level and reduce damage of Hcy. The composition provides an effective scheme for treating hyperhomocysteinemia or diseases accompanied with homocysteine rise. The invention belongs to the field of pharmacy.

The invention discloses an application of lactobacillus rhamnosus CCFM1060 in preparation of functional microbial agents, foods and / or medicines. The lactobacillus rhamnosus CCFM1060 can tolerate thegastrointestinal environment of the human body, significantly improve fasting blood glucose rise and abnormal oral glucose tolerance of type 2 diabetics caused by high fat diet and STZ injection, reduce the area under the curve during glucose tolerance drug administration, and relieve insulin resistance; remarkably improve the increase of total cholesterol content and the increase of low-density lipoprotein cholesterol in serum of type 2 diabetics caused by high-fat diet and STZ injection; obviously relieve the inflammatory state of the liver; and significantly reduce pancreatic and liver pathological injuries caused by high-fat diet and STZ injection. The lactobacillus rhamnosus CCFM1060 has relatively strong adsorption capacity on perfluorooctanoic acid (PFOA), and has the capacity of relieving the toxicity of the PFOA.

Provided is a strain CCFM8630 of Bifidobacterium adolescentis and use thereof. The strain CCFM8630 of Bifidobacterium adolescentis can significantly increase neurotransmitter 5-hydroxytryptamine level in peripheral blood of rat, recover the hormone levels, for example testosterone and so on in peripheral blood of rat, normalize abnormal abundances of Bifidobacterium genus, Blautia genus and Turicibacter genus in intestinal flora of rat affected by high-fat high-starch diet, show pretty good tolerance to simulated gastrointestinal fluid and quickly colonize in intestinal, significantly improve pathological damages of tissues such as liver, duodenum and so on, and increase triglyceride and total cholesterol levels in serum and oral glucose tolerance of rat with metabolic syndrome caused by high-fat high-starch diet. The strain CCFM8630 of Bifidobacterium adolescentis can be used for preventing, relieving or treating metabolic disorder, such as metabolic syndrome, irritable bowel syndrome and mental diseases related to metabolic syndrome such as anxiety, depression and so on.

The present invention relates to a compound medicine granule preparation for effectively curing entero toxemia and its preparation method. Its composition includes the following main components: rhubarb 0.1-10kg, bitter orange 0.1-8kg, magnolia bark 0.1-8kg and mirabilite 0.01-3kg. Said invention also provides the concrete steps of its preparation method.

The invention provides a medicament for treating infectious diseases, a preparation method and the application thereof. The medicament is prepared from scutellaria baicalensis, jasmine, erigeron breviscapus and cholic acid, and has the following effects: by aiming at the central link--inflammatory reaction of an infectious disease, removing harmful substances such as inflammatory mediators, free radicals and the like, and improving the local microcirculation state, thereby alleviating the pathological damages caused by inflammations; meanwhile, the medicament has the function of regulating the overall internal environment, and can effectively treat lower respiratory tract infection and acute lung injury induced by infection; and the effective substances and functional mechanism of the medicament are relatively clear.

The invention discloses an antagonistic drug against replication of a porcine reproductive and respiratory syndrome virus (PRRSV) and application of the antagonistic drug. A virus infection test is adopted, and Xanthohumol (Xn), the antagonistic drug of the PRRSV, is discovered for the first time from a natural medicine library with 386 plant sources. The drug can effectively inhibit PRRSV replication in both Marc-145 and PAM cells, five xanthohumol derivatives with different molecular structures are artificially synthesized, and the viral infection test further finds that the inhibition effect to virus replication by drug derivative Xn-4 is highest in vitro; and test results of artificial infection and drug therapy in piglets show that the Xn-4 can effectively inhibit PRRSV viremia, relieves clinical symptoms of infected pigs, and significantly reduces pulmonary inflammation and pathological damage. Combined with the results, it is proved that the antagonistic drug has important preventive and therapeutic effects to a porcine reproductive and respiratory syndrome, and has important application prospects.

The present invention relates to a preparation method of polyporus polysaccharide sulfate. Said method includes the following steps: (1). preparing esterification reagent; (2). selecting and using polyporus polysaccharide powder and anhydrous methanamide or dimethyl methanamide according to mass ratio of 0.4-2.0:36-48, making the polyporus polysaccharide powder be suspended in anhydrous methanamide or dimethyl methanamide to obtain polyporus polysaccharide suspension; (3). making esterification reaction; (4). precipitation; (5). purifications and (6). secondary precipitation. Besides, said invention also provides the concrete requirement of every step.

The invention discloses a novel low-toxicity tripterygium polyglycoside. The novel low-toxicity tripterygium polyglycoside is obtained via chemical processing and adding of triptolide. The invention also discloses applications of the novel low-toxicity tripterygium polyglycoside in the field of medicine. The novel low-toxicity tripterygium polyglycoside is capable of relieving nephrotic syndromes such as kidney pathological injury and proteinuria, improving body inflammation level, possesses obvious curative effect on nephrotic syndromes, is low in toxicity, and effect lasts long.

The invention belongs to the technical field of immunotherapy, and discloses a drug for treating sepsis, which is characterized in that the drug can inhibit 14-3-3 protein. According to the invention,14-3-3 molecules are used as targets to be applied to treatment of sepsis for the first time. Immunotherapy of sepsis can be achieved through the 14-3-3 targeting method. The method has the advantages of improving the survival rate of sepsis, relieving inflammation and the like, is suitable for comprehensive treatment of sepsis and is suitable for clinical application and popularization.

The invention discloses an application of epigallocatechin gallate (EGCG) in preparing a drug for resisting a respiratory syncytial virus (RSV), and belongs to the field of antiviral drugs. According to the application, it is discovered that the EGCG can inhibit RSV infection both in vitro and in vivo and is free of toxic and side effects; in vitro, the EGCG can prevent cells from being infected by the RSV and inhibit biosynthesis of the RSV in the cells; in vivo, the EGCG can alleviate lung tissue pathological lesion caused by RSV infection and lower the virus titer of the RSV in the lung tissue. The discovery proves that the EGCG can be used for preparing the drug for resisting the RSV and also can be used for preparing a drug for treating and / or preventing pulmonary diseases caused by the RSV.

The invention provides an application of inhibitor of histone deacetylase HDAC 6 in preparing drugs for preventing and treating acute kidney injury. Furthermore, the histone deacetylase HDAC 6 is Tubastatin A. The selective inhibitor of HDAC 6 can lighten the renal pathology damage of acute kidney injury induced by cis-platinum and improve the kidney function. The HDAC6 inhibitor TA can lower the release of inflammatory factors and lighten the oxidative stress reaction through regulating an AKT signal access, an NF-KB inflammation access, an autophagy level and an E-cadherin expression; thus the apoptosis of kidney tubule cell and necrosis of tubule expansion are reduced, the renal pathology damage and kidney function are improved; the inhibitor can protect the kidney structure and function in the acute kidney injury. Therefore, HDAC6 is likely to be an important target point to prevent and treat the acute kidney injury.

The invention relates to the technical field of porcine circovirus, in particular to a porcine circovirus 2 (PCV2) immune protection polypeptide, and a vaccine containing the PCV2 immune protection polypeptide. The amino acid sequence of the PCV2 immune protection polypeptide is shown in the sequence table 1-4. According to the vaccine, tests show that after 42-63 days of first immune of a vaccine of P5013 and a vaccine of P1300, the antibody titer and the neutralizing antibody titer of an ELISA antibody are remarkably increased, the lymphocyte proliferative response and IL-4 and IFN-Gamma cytokines are significantly higher than those of a control group, and the antibody level and the cellular immunity level of the vaccine group of P5013 are the highest; mice tests show that PCV2 immune response induced by the synthetic peptide vaccine of P5013 is the highest and the strongest; pig tests find that the synthetic polypeptide vaccine of P5013 can induce pigs to generate a PCV2-specific immune response, can reduce viremia caused by PCV2 virulent virus attack, alleviate the clinical symptoms and pathological lesions of viremia, and has immune protection effect on PCV2.

The invention provides traditional Chinese medicine colon dialyzate treating chronic renal failure. The traditional Chinese medicine colon dialyzate comprises, by weight, 10-30 parts of astragalus membranaceus, 15-45 parts of angelica sinensis, 10-30 parts of codonopsis pilosula, 5-15 parts of ligusticum wallichii, 12-30 parts of raw rhubarb, 12-30 parts of raw oyster shell, 15-30 parts of dandelion, 5-15 parts of ganoderma lucidum, 6-10 parts of herb of snow of june, 3-9 parts of resina draconis, 3-9 parts of ternate buttercup root and 3-6 parts of ambrette musk mallow. The clinic experiment proves that the traditional Chinese medicine colon dialyzate has an obvious curative effect on treating the chronic renal failure. The traditional Chinese medicine colon dialyzate has a small number of adverse reactions, has the advantages of being high in safety, low in cost, convenient to operate and the like and is a safe and effective new method for treating the chronic renal failure.

The invention relates to nitric oxide donor type hexadecadrol as well as a preparation method and application thereof. The nitric oxide donor type hexadecadrol as a compound is obtained by enabling nitrous acid ester to be connected with hexadecadrol through ethyl cyclohexanecarboxylate; the in-vitro antiinflammatory activity of the nitric oxide donor type hexadecadrol is better than that of the hexadecadrol; besides, the nitric oxide donor type hexadecadrol can restrain the growth of methicillin-resistant staphylococcus aureus (MRSA) in vitro, restrain the formation of MRSA biomembrane, and lead to the death of bacteria in the MRSA biomembrane. In addition, the compound can notably increase the survival rate of mice in MRSA sepsis lethal models, reduces the inflammation pathology damage of the mice in sub-sepsis models, decreases the constant value number of bacteria, and has notable advantages in the respect of preventing and treating MRSA sepsis.

The invention relates to a novel application of niclosamide ethanolamine salt, and in particular to the application of the niclosamide ethanolamine salt in preparing medicines for preventing and treating diabetes type 1 and complications thereof; and the invention also conducts studies on the protective effect and the action mechanism of the niclosamide ethanolamine salt on the diabetes type 1 and the complications thereof. Results show that the niclosamide ethanolamine salt can improve symptoms of polyuria, polydipsia and polyphagia in a mouse with the diabetes type 1, reduce blood glucose, glycosylated hemoglobin and urine glucose levels, increase a serum insulin level and improve pancreas pathological damage. In the aspect of protecting a kidney target organ, the niclosamide ethanolamine salt can reduce a urinary albumin excretion rate, lower a creatinine clearance rate, diminish the area of glomerular vascular loops, reduce NAG and NGAL discharge in urine and inhibit activation of Akt / mTOR / 4E-BP1 signaling pathways in kidney tissues. In addition, the niclosamide ethanolamine salt can also take an obvious protecting effect on liver and achieve a significant improving effect on muscle functions. Therefore, the niclosamide ethanolamine salt has a significant protective effect on the diabetes type 1 and the complications thereof.

The invention provides an immunologic adjuvant. The immunologic adjuvant is composed of cationic liposome dimethyl trihexadecyl alkylammonium (DDA), PolyI: C and cholesterol. According to the immunologic adjuvant provided by the invention, a novel vaccine adjuvant DDA+PolyI: C+cholesterol (DPC for short) is constructed by combining cholesterol with DDA and polyI: C through screening reagents capable of enhancing the stability of the adjuvants and giving consideration to both immunocompetence and clinical application of a vaccine, thus improving the stabilities of the adjuvants DDA and polyI: C, and the particle size is less than that of DDA+PolyI: C (DP for short), thus facilitating the performances of later-period development and production; the immunologic adjuvant is combined with fusion protein LT70 to construct a tuberculosis subunit vaccine LT-70-DPC, and the overall protection effect is found to be higher than those of BCG and LT70-DP.

The invention discloses an application of a mixture of lactobacillus plantarum capable of degrading tryptophan and tryptophan, and specifically discloses an application of the mixture of lactobacillusplantarum capable of degrading tryptophan and tryptophan to reducing the activity of myeloperoxidase MPO in colon tissue, an application of the mixture of lactobacillus plantarum capable of degradingtryptophan and tryptophan to improving immune response disorder of colitis, an application of the mixture of lactobacillus plantarum capable of degrading tryptophan and tryptophan to protecting intestinal barriers, an application of the mixture of lactobacillus plantarum capable of degrading tryptophan and tryptophan to protecting intestinal mucosa and an application of the mixture of lactobacillus plantarum capable of degrading tryptophan and tryptophan to regulating intestinal microorganisms. Through in vitro assessment of the degrading capacity of 16 pieces of lactobacilli on the tryptophan, lactobacillus plantarum KLDS1.0386 having high tryptophan degrading capacity is screened out, and the lactobacillus plantarum KLDS1.0386 has good growth properties, has high acid production capacity, acid resistance and cholate resistance, and shows favorable probiotic functions and colitis preventing functions.

The invention discloses a traditional Chinese medicinal compound for controlling animal mycotoxin poisoning. The traditional Chinese medicinal compound treats Phyllanthus urinaria L, Chinese Taxillus Twig, Himalayan Teasel Root, Herba Sedi, Chinese magnoliavine and Chinese yam as raw materials, and is obtained through primarily extracting the raw materials according to different characteristics of all the raw materials, uniformly mixing the obtained extract products of the raw materials in proportion, and carrying out vacuum drying to prepare a pulvis. The traditional Chinese medicinal compound has the advantages of unique and scientific formula and technology, and substantial treatment effect.

The invention relates to application of shizandra extract in curing alcoholic liver, which is used for curing the alcoholic liver. The shizandra extract can be used as medicine for preventing and curing the alcoholic liver. The shizandra extract comprises active ingredients and medicine carrier compositions. The preparation formulations which can be prepared by the shizandra extract are tablets, capsules, solution, suspension, injection or dropping liquid and so on which can be accepted pharmaceutically. The shizandra extract is characterized by low toxicity and has no defect of secondary harm on the liver of other alcoholic liver resistant drugs.

The invention discloses application of a polyinosinic-polycytidylic acid (poly I:C) combined dimo-thylidioctyl ammonium bromide (DDA) mixed adjuvant to the preparation of tuberculosis subunit vaccines. The invention has the advantages that: the mixed adjuvant DDA / Poly I:C can enhance the secretion level of antigenic specificity interferon-gamma (IFN-gamma) of fusion protein Ag85B-MPT64190-198-Mtb8.4 (AMM) effectively and relieve pathological damage caused by H37Rv infection, and is an effective adjuvant of vaccines for preventing tuberculosis.

The invention discloses pediococcus acidilactici for improving the production performance and immune level of broiler chickens and a screening method and application thereof. The invention provides a novel pediococcus acidilactici screening method and pediococcus acidilactici LC-9-1 screened by the method by improving a screening procedure and adopting an in-vitro and in-vivo combined strategy. In-vivo tests prove that the pediococcus acidilactici LC-9-1 has the following application effects: the safety is high, the stress resistance is strong, the pediococcus acidilactici LC-9-1 is easy to colonize in intestinal tracts, the intestinal flora structure can be improved, the development of the intestinal tracts can be promoted, the pathological injury of the liver and the spleen can be relieved, the growth performance and the immune performance can be improved, and the effect of replacing AGPs can be achieved to a certain extent.

The invention discloses an application of Elabela polypeptide in preparation of a medicine or functional food for preventing and / or treating diseases related to chronic kidney injury and the medicinethereof. The diseases related to chronic kidney injury comprise (i) chronic renal insufficiency caused by hypertension; or ii) chronic renal insufficiency with hypertension. The Elabela polypeptide isstable in blood pressure reduction, can effectively relieve glomerular pathological injury of SD rats induced by deoxycorticosterone, reduce discharge of urine microalbumin, relieve development of renal fibrosis and reduce expression of inflammatory factors in kidney tissues, and has a remarkable effect on treatment of chronic kidney injury. Meanwhile, the Elabela polypeptide is an endogenous hormone synthesized by a human body and is expressed in kidney tissue, so that the toxic and side effects are smaller than those of the existing medicine for treating chronic kidney injury.

The invention belongs to the field of pharmacy and particularly relates to use of a DNA-dependent protein kinase specific inhibitor in the preparation of drugs to prevent and treat renal fibrosis. Furthermore, the DNA-dependent protein kinase activity inhibitor is NU7441. The DNA-PK activity inhibitor herein is a DNA-PK catalytic subunit selective inhibitor, which helps relieve renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction, and improve the renal functionality. The NU7441 inhibitor can inhibit DNA-PK activation specifically so as to inhibit abnormal activation ofmTOR, inhibit the epithelial-mesenchymal transition of renal tubular epithelial cells, inhibit the collagen generation of renal tubular epithelial cells and mesenchymal fibroblasts under TGF-beta 1 stimulation, improve renal pathological injury and renal function, and improve renal tubulointerstitial fibrosis. The effective clinical drugs to prevent and treat renal fibrosis-related diseases are provided herein.

The invention discloses application of bicyclol as shown in the formula (I) to preparation of a drug for treating and / or preventing diabetes.

The invention discloses a traditional Chinese medicine composition for treating egg drop disease of laying hen and a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following medcinal raw materials in parts by weight: 15 to 20 parts of salvia miltiorrhiza, 10 to 12 parts of safflower carthamus, 10 to 15 parts of leonurus, 5 to 7 parts of rhizoma sparganii, 5 to 7 parts of curcuma zedoary, 15 to 20 parts of herba epimedii, 15 to 20 parts of fructus cnidii, 15 to 20 parts of rhizoma curculiginis and 10 to 13 parts of polygonum cuspidatum. The traditional Chinese medicine composition for treating egg drop disease of laying hen and the preparation method and application thereof are mainly used for treating the egg drop disease of the laying hen with a clear target; the traditional Chinese medicine composition is reasonable in compatibility of medicinal raw materials, and simple to process, used in a way of being mixed with feed, and has an remarkable effect of preventing and treating the egg drop disease of the laying hen.

The invention discloses a use of a hypoxia-inducible factor prolyl hydroxylase activity inhibitor in the preparation of a drug for preventing and treating acute kidney injury. The HIF prolyl hydroxylase activity inhibitor is Roxadustat (FG-4592). The HIF prolyl hydroxylase activity inhibitor is an HIF family selective inhibitor, and can alleviate pathological damages of cisplatin-induced acute kidney injury to kidneys and improve the functions of the kidneys. The FG-4592 can reduce apoptosis of renal tubular cells and renal tubular functions, improve the pathological injury and renal functionsof the kidneys and protect the structures and the functions of the kidneys in the acute kidney injury by activating HIF1alpha, promoting the expression of EPO and HO-1, inhibit apoptosis and down-regulate the release of inflammatory factors. The FG-4592 is currently in a Phase III clinical research stage in the field of prevention and treatment of chronic renal anemia, and it is found that the FG-4592 is highly possible to provide the effective clinical drug for preventing and treating the AKI.

The invention relates to a rosa roxburghii active extract with an anti-depression effect and application. The active extract is obtained from rosa roxburghii fruits or rosa roxburghii fruit residues by adopting a chemical extraction or membrane separation technology, wherein the chemical extraction technology comprises the following steps of: performing alcohol reflux extraction on freshly squeezed rosa roxburghii fruit residues or rosa roxburghii fruits, filtering, concentrating to remove ethanol, adding water to disperse water-insoluble precipitates, filtering, washing the precipitates by using water and petroleum ether or n-hexane in sequence, removing water-soluble substances and grease, and drying, thereby obtaining the active extract. The active extract contains triterpene and flavone components, and the research finds that the active extract is obvious in anti-depression activity, can be used for preparing anti-depression medicines and auxiliary medicines or serving as a healthy food additive and has high application values and market prospects. The active extract disclosed by the invention has significance for high-value utilization and sustainable development of the rosa roxburghii industry, an intermediate or additive raw material is provided for the anti-depression medicines or health foods, and the preparation method is simple and feasible, low in cost and capable of realizing industrial production.

The invention discloses an application of disulfiram to preparation of a drug for treating systemic lupus erythematosus. For the systemic lupus erythematosus, a lupus mouse model induced by pristane is taken as an experiment object. According to the application, the disulfiram can effectively improve the disease condition of a lupus mouse, and specific performances are as follows: (1) the urine protein level of the lupus mouse after being treated with the disulfiram is significantly reduced; (2) the disulfiram can reduce the level of a peripheral blood anti-dsDNA and the level of an inflammatory factor IL-1beta of the lupus mouse; and (3) after intervention is carried out by using the disulfiram, pathological damage to kidney of the lupus mouse is significantly reduced, and immune complexIgG and C3 deposits are also reduced.

The present invention discloses a Chinese medicine for curing chronic nephritis and chronic renal insufficiency with obvious therapeutic effect and small size effect. Said invention is made up by using 7 Chinese medicinal materials of centella, cornus fruit, ligusticum root, astragalus root, salvia root and others.